Aigen Investment Management LP Buys 35,937 Shares of Pfizer Inc. (NYSE:PFE)

Aigen Investment Management LP lifted its stake in Pfizer Inc. (NYSE:PFE) by 95.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 73,486 shares of the biopharmaceutical company’s stock after purchasing an additional 35,937 shares during the quarter. Aigen Investment Management LP’s holdings in Pfizer were worth $1,950,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP boosted its holdings in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the period. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer during the 4th quarter worth $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new position in shares of Pfizer during the 3rd quarter worth $35,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 2.0 %

Shares of PFE stock opened at $25.72 on Wednesday. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company’s fifty day simple moving average is $26.32 and its two-hundred day simple moving average is $27.28. The stock has a market cap of $145.73 billion, a P/E ratio of 18.24, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 earnings per share. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.69%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 121.99%.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on PFE shares. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.